Hepatitis C and liver fibrosis.

Area of Science:

• Hepatology and Viral Gastroenterology
• Molecular Biology and Immunology
• Pharmacology and Drug Development

Background:

• Chronic hepatitis C (HCV) infection can progress to liver cirrhosis in 20-30% of patients within 20 years.
• HCV proteins (core, NS5A) disrupt lipid metabolism and signal transduction, increasing oxidative stress and profibrogenic mediators like TGF-beta1.
• Fibrogenesis is amplified by co-factors such as alcohol, metabolic disorders (NASH), and coinfections (HIV, Schistosoma mansoni), as well as genetic polymorphisms.

Purpose of the Study:

• To elucidate the mechanisms of HCV-induced liver fibrosis.
• To identify patient subgroups at high risk for fibrosis progression.
• To explore novel therapeutic strategies for liver fibrosis beyond current antiviral treatments.

Main Methods:

• Analysis of molecular pathways involved in HCV pathogenesis, including lipid metabolism, signal transduction, and oxidative stress.
• Investigation of the role of TGF-beta1 and other profibrogenic mediators in hepatic stellate cell activation.
• Review of existing and potential antifibrotic therapies, including cytokine-based strategies and adjunctive agents.

Main Results:

• HCV proteins contribute to fibrogenesis through oxidative stress and TGF-beta1 induction.
• Co-factors and genetic predispositions significantly influence fibrosis progression.
• Current treatments (pegylated interferon/ribavirin) achieve only 50% HCV eradication rates and have limitations.

Conclusions:

• Identifying patients at risk for rapid fibrosis progression is crucial for timely intervention.
• Combination therapies targeting TGF-beta1 and utilizing novel antifibrotic agents show promise.
• Development of well-tolerated, cost-effective antifibrotic strategies and targeted drug delivery is essential for personalized liver fibrosis management.